Xia Lin-Yu, Cao Xu-Chen, Yu Yue
The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
Sci Rep. 2025 Jun 4;15(1):19595. doi: 10.1038/s41598-025-03487-6.
It is reported that HER2-low breast cancer (BC) demonstrates a poor response to neoadjuvant chemotherapy (NACT), whereas the response and impact of HER2-low triple-negative breast cancer (TNBC) to NACT remain controversial. TNBC patients who received standard NACT at Tianjin Medical University Cancer Hospital were retrospectively enrolled. The pathological complete response (pCR) rate of NACT were compared between HER2-low and HER2-zero patients. Logistic regression analyses were performed to identify the independent factors affecting the pCR rate in patients with HER2-low TNBC after NACT. We finally included 369 HER2-low and 245 HER2-zero patients with TNBC. The axillary lymph nodes pathological complete response (npCR) rate and total pathological complete response (tpCR) rate after NACT in the HER2-low group were worse than that in the HER2-zero group, and there was no statistical difference in breast pathological complete response (bpCR) between the two groups. In HER2-low TNBC patients, multivariate analysis showed that early clinical lymph node stage, high Ki67 expression, use of immunotherapy and bpCR were independent influencing factors for npCR. Premenopause, small clinical tumor size, early clinical lymph node stage, CK5/6 positivity and EGFR negativity were independent factors affecting tpCR. The npCR and tpCR of HER2-low TNBC patients are worse than those of HER2-zero TNBC patients.
据报道，HER2低表达乳腺癌（BC）对新辅助化疗（NACT）反应不佳，而HER2低表达三阴性乳腺癌（TNBC）对NACT的反应和影响仍存在争议。对在天津医科大学肿瘤医院接受标准NACT的TNBC患者进行回顾性纳入研究。比较HER2低表达和HER2零表达患者NACT的病理完全缓解（pCR）率。进行逻辑回归分析以确定影响HER2低表达TNBC患者NACT后pCR率的独立因素。我们最终纳入了369例HER2低表达和245例HER2零表达的TNBC患者。HER2低表达组NACT后的腋窝淋巴结病理完全缓解（npCR）率和总病理完全缓解（tpCR）率均低于HER2零表达组，两组间乳腺病理完全缓解（bpCR）无统计学差异。在HER2低表达TNBC患者中，多因素分析显示早期临床淋巴结分期、高Ki67表达、免疫治疗的使用和bpCR是npCR的独立影响因素。绝经前、临床肿瘤体积小、早期临床淋巴结分期、CK5/6阳性和EGFR阴性是影响tpCR的独立因素。HER2低表达TNBC患者的npCR和tpCR均低于HER2零表达TNBC患者。
